{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:16:07Z","timestamp":1718219767493},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"DOI":"10.2146\/ajhp160279","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T10:40:30Z","timestamp":1498214430000},"page":"970-976","source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular safety outcomes of new antidiabetic therapies"],"prefix":"10.1093","volume":"74","author":[{"given":"Marlys H.","family":"LeBras","sequence":"first","affiliation":[{"name":"RxFiles Academic Detailing Program, Saskatoon Health Region, Saskatoon, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arden R.","family":"Barry","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, and Chilliwack General Hospital, Lower Mainland Pharmacy Services, Chilliwack, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri L.","family":"Koshman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103304629000_b1-0740970","unstructured":"International Diabetes Federation. Diabetes atlas, seventh edition, 2015. www.diabetesatlas.org (accessed 2017 Apr 18)."},{"key":"key\n\t\t\t\t2019041103304629000_b2-0740970","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/dc12-2625","article-title":"Economic costs of diabetes in the U.S. in 2012","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041103304629000_b3-0740970","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b4-0740970","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041103304629000_b5-0740970","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b6-0740970","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041103304629000_b7-0740970","unstructured":"Food and Drug Administration. Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov\/downloads\/drugs\/guidancecompli-anceregulatoryinformation\/guid-ances\/ucm071627.pdf (accessed 2015 Nov 6)."},{"key":"key\n\t\t\t\t2019041103304629000_b8-0740970","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities","volume":"13","author":"Singh","year":"2012","journal-title":"Trials"},{"key":"key\n\t\t\t\t2019041103304629000_b9-0740970","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","article-title":"Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes","volume":"383","author":"Holman","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103304629000_b10-0740970","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b11-0740970","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b12-0740970","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b13-0740970","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103304629000_b14-0740970","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103304629000_b15-0740970","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized controlled trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t2019041103304629000_b16-0740970","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b17-0740970","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041103304629000_b18-0740970","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b19-0740970","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b20-0740970","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103304629000_b21-0740970","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/2012.jama.11235","article-title":"How to use a noninferiority trial: user\u2019s guides to the medical literature","volume":"308","author":"Mulla","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041103304629000_b22-0740970","unstructured":"ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730534 (accessed 2016 Jul 14)."},{"key":"key\n\t\t\t\t2019041103304629000_b23-0740970","unstructured":"ClinicalTrials.gov. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease, the VERTIS CV Study (MK-8835-004). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01986881 (accessed 2016 Jul 14)."},{"key":"key\n\t\t\t\t2019041103304629000_b24-0740970","unstructured":"ClinicalTrials.gov. Canagliflozin cardiovascular assessment study (CANVAS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01032629 (accessed 2017 Apr 18)."},{"key":"key\n\t\t\t\t2019041103304629000_b25-0740970","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1479164111408937","article-title":"Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2\u20133 liraglutide clinical development studies","volume":"8","author":"Marso","year":"2011","journal-title":"Diab Vasc Dis Res"},{"key":"key\n\t\t\t\t2019041103304629000_b26-0740970","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","article-title":"Anti-diabetic treatment with gliptins: focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t2019041103304629000_b27-0740970","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jchf.2014.04.005","article-title":"Sitagliptin use in patients with diabetes and heart failure","volume":"2","author":"Weir","year":"2014","journal-title":"JACC Heart Fail"},{"key":"key\n\t\t\t\t2019041103304629000_b28-0740970","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2014.09.038","article-title":"Sitagliptin and the risk of hospitalization for heart failure: a population-based study","volume":"177","author":"Wang","year":"2014","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019041103304629000_b29-0740970","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","article-title":"Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study","volume":"346","author":"Eurich","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041103304629000_b30-0740970","unstructured":"Hicks KA Hung HM Mahaffey KW . Standardized definitions for end points in cardiovascular trials. www.cdisc.org\/system\/files\/all\/standard\/Draft%20Definitions%20for%20CDISC%20August%2020,%202014.pdf (accessed 2015 Nov 6)."},{"key":"key\n\t\t\t\t2019041103304629000_b31-0740970","unstructured":"Food and Drug Administration. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. www.fda.gov\/Drugs\/DrugSafety\/ucm486096.htm (accessed 2016 Apr 7)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/13\/970\/28337575\/ajhp0970.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T18:46:16Z","timestamp":1569523576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/13\/970\/5102540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160279","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,1]]},"published":{"date-parts":[[2017,7,1]]}}}